Displaying drugs 7226 - 7250 of 13634 in total
rGLP-1
rGLP-1 is a continuous infusion of glucagon-like peptide 1, or GLP-1, targeted for the treatment of congestive heart failure (CHF) in patients ineligible for transplant. GLP-1 is a naturally occurring hormone produced in the intestines in response to food intake.
Investigational
Matched Description: … heart failure (CHF) in patients ineligible for transplant. ... GLP-1 is a naturally occurring hormone produced in the intestines in response to food intake. ... rGLP-1 is a continuous infusion of glucagon-like peptide 1, or GLP-1, targeted for the treatment of congestive …
WL-1002
WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin (also known as civamide), for the treatment of pain due to osteoarthritis.
Investigational
Matched Description: … (also known as civamide), for the treatment of pain due to osteoarthritis. ... WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin …
5-phenyl-1H-indazol-3-amine
Experimental
Flurbiprofen axetil
Flurbiprofen axetil is under investigation in clinical trial NCT02043366 (Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients).
Investigational
Matched Description: … With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients). ... Flurbiprofen axetil is under investigation in clinical trial NCT02043366 (Effect of Butorphanol Combined …
Acid yellow 54 free acid
Experimental
N-acetylhistamine
Experimental
QR-333
QR-333 has been investigated as a treatment for diabetic peripheral neuropathy. QR-333 is a concentrated and standardized nutrient based active compounds dosed in a topical cream designed to reduce oxidative stress and treat symptoms of Diabetic Peripheral Neuropathy, a nerve disorder that can lead to numbness, skin ulcers, constant pain...
Investigational
Matched Description: … QR-333 has been investigated as a treatment for diabetic peripheral neuropathy. ... QR-333 is a concentrated and standardized nutrient based active compounds dosed in a topical cream designed ... can lead to numbness, skin ulcers, constant pain or extreme sensitivity to a stimulus. …
APD791
APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena. APD791 is intended to lower the risk of arterial thrombosis by reducing the amplification of platelet aggregation, arterial constriction and intimal hyperplasia mediated by serotonin.
Investigational
Matched Description: … APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena …
PEV3A
PEV3A is a prophylactic malaria vaccine that acts against various stages of the disease. It is a two-component vaccine that contains the virosome formulated peptide mimetics PEV301 and PEV302. The two synthetic peptide vaccine components mimic the native structure of important antigens of the malaria parasite. The elicited antibodies are...
Investigational
Matched Description: … PEV3A is a prophylactic malaria vaccine that acts against various stages of the disease. ... It is a two-component vaccine that contains the virosome formulated peptide mimetics PEV301 and PEV302 …
Adagloxad simolenin
Adagloxad simolenin is under investigation in clinical trial NCT03562637 (Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC).
Investigational
Matched Description: … (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC). ... Adagloxad simolenin is under investigation in clinical trial NCT03562637 (Study of Adagloxad Simolenin …
PLX51107
PLX51107 is a potent and selective inhibitor of the bromodomain and extraterminal (BET) protein family.[A257246,A257251] PLX51107 is under investigation in clinical trial NCT04022785 (PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome).
Investigational
Matched Description: … PLX51107 is a potent and selective inhibitor of the bromodomain and extraterminal (BET) protein family ... in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome). ... [A257246,A257251] PLX51107 is under investigation in clinical trial NCT04022785 (PLX51107 and Azacitidine …
3-Cyclohexyl-L-alanine
Experimental
Aluminium tristearate
Experimental
Vet approved
Tricarballylic acid
Experimental
Apitegromab
Apitegromab is under investigation in clinical trial NCT03921528 (An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy).
Investigational
Matched Description: … in Patients With Type 2 or Type 3 Spinal Muscular Atrophy). ... Apitegromab is under investigation in clinical trial NCT03921528 (An Active Treatment Study of SRK-015 …
Tributyrin
Tributyrin has been used in trials studying the treatment of Prostate Cancer and Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
Matched Description: … Tributyrin has been used in trials studying the treatment of Prostate Cancer and Unspecified Adult Solid …
Fipaxalparant
Investigational
Stepronin
Strepronin is a mucolytic drug. A mucolytic agent is any agent which dissolves thick mucus usually used to help relieve respiratory difficulties. The viscosity of mucous secretions in the lungs is dependent upon the concentrations of mucoprotein as well as the presence of disulfide bonds between these macromolecules and DNA.
Experimental
Matched Description: … Strepronin is a mucolytic drug. ... The viscosity of mucous secretions in the lungs is dependent upon the concentrations of mucoprotein as ... A mucolytic agent is any agent which dissolves thick mucus usually used to help relieve respiratory difficulties …
NRC-AN-019
Investigational
1-Ethyl-Pyrrolidine-2,5-Dione
Experimental
7-cyano-7-deazaguanine
Experimental
SGN-30
SGN-30 is an engineered monoclonal antibody (mAb) that reacts with significant affinity to the CD30 antigen, which is highly expressed on a variety of hematologic malignancies as compared to on normal cells. SGN-30 has been shown to induce direct anti-cancer activity towards tumor cells expressing CD30 and is undergoing phase...
Investigational
Matched Description: … SGN-30 has demonstrated objective antitumor responses as a single agent in phase II clinical trials. ... SGN-30 received orphan drug designation from the FDA in July 2003 for Hodgkin lymphoma and in February ... 2004 for T-cell lymphomas. …
Imidazole
Experimental
Investigational
Matched Categories: … Thromboxane-A Synthase, antagonists & inhibitors …
(S)-Aspartimide
Experimental
Displaying drugs 7226 - 7250 of 13634 in total